Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

Thomas Bachelot, C. Bourgier, Claire Cropet, +11

Journal of Clinical Oncology

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

Prudence A. Francis, Olivia Pagani, Gini F. Fleming, +33

New England Journal of Medicine

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im, +56

The Lancet Oncology

First-line TherapyBreast OncologyMedicinePharmacologyClinical Trials +5

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-up

L. Mauriac, Gaëtan MacGrogan, A. Avril, +5

Annals of Oncology

Surgical OncologyOncologyNeoadjuvant ChemotherapyBreast Oncology124-Month Median Follow-up +7

Variables with time-varying effects and the Cox model: Some statistical concepts illustrated with a prognostic factor study in breast cancer

Carine Bellera, Gaëtan MacGrogan, Marc Debled, +3

BMC Medical Research Methodology

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

Meredith M. Regan, Brian Leyland‐Jones, Mark Bouzyk, +17

JNCI Journal of the National Cancer Institute

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

X. Pivot, Gilles Romieu, Marc Debled, +17

The Lancet Oncology

Breast OncologyMedicineRandomised Phase 3Clinical TrialsBreast Cancer +3

Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort

Élisa Gobbini, Monia Ezzalfani, Véronique Dièras, +25

European Journal of Cancer

Prognostic EvaluationBreast OncologyMedicineTime TrendsEpidemiology Of Cancer +7

Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence

Jacquie Chirgwin, Anita Giobbie‐Hurder, Alan S. Coates, +12

Journal of Clinical Oncology

Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort

Amélie Darlix, G. Louvel, Julien Fraisse, +22

British Journal of Cancer